PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 1, 20240 citationsOpen Access

Figure S11 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

View Full Paper
MAMinae AnAMArnav MehtaBMByung‐Hoon Min

Key Points

Key points are not available for this paper at this time.

Abstract

Figure S11. Mean usage of myeloid cNMF programs per myeloid cell subset at (A) baseline, (B) post-chemotherapy (FU1) and (C) post-immunotherapy (FU2). Mean usage of T cell cNMF programs per T cell cell subset at (D) baseline, (E) postchemotherapy (FU1) and (F) post-immunotherapy (FU2).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

An et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4bab6db643587643a90https://doi.org/10.1158/2159-8290.25729029.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Figure S12 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
  2. 2Figure S10 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
  3. 3Figure S13 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
  4. 4Figure S27 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024
  5. 5Figure S14 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer2024